Seaport Completes Spin-Off from PureTech and Raises $100 Million in Series A Financing 

Seaport Completes Spin-Off from PureTech and Raises $100 Million in Series A Financing 

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale represented Seaport Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing novel neuropsychiatric medicines, in connection with its spin-off from PureTech Health and its $100 million oversubscribed Series A financing round. The transactions enable Seaport to progress its pipeline of novel neuropsychiatric medicines based on its Glyph™ Technology Platform, which is designed to enable and enhance oral bioavailability, avoid first-pass metabolism and reduce hepatotoxicity and other side effects to advance active drugs that were previously held back by those limitations. The financing was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and PureTech. The WilmerHale team representing Seaport consisted of Stuart Falber, Sarah Hogan, Will Myer, Pooja Sudarshan, Adam Camiel, Ben Goldfein, Matthew O’Malley, Scott Kilgore, Julie Hogan Rodgers and Kim Wethly.  

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel